

# CUMULATIVE INDEX 1994

## Volume 12

February	CONGESTIVE HEART FAILURE, pages 1-168
May	NUCLEAR CARDIOLOGY, pages 169-398
August	ANTICOAGULANT/ANTIPLATELET THERAPY AND CARDIOVASCULAR DISEASE, pages 399-541
November	CONTEMPORARY INTERVENTIONAL TECHNIQUES, pages 543-756

Note: Page numbers for complete issues and articles are in **boldface** type.

- Abiomed biventricular support system, 148-149  
 Ablation, high-speed rotational, **595-610**. See also  
     *Catheter, rotablator*.  
     analysis of, 597-600  
     arterial wall effects of, 597-598  
     burr size-coronary dimensions, 600  
     issues unique to, 607-608  
     microcavitations produced by, 599-600  
     microparticulate debris and, 598-599  
     physical principles of, 596-597  
 ACE inhibitors. See *Angiotensin-converting enzyme (ACE)*  
     inhibitors.  
 Acetate, C-11, 181  
     oxidative metabolism measurement with, 309  
 Acetylsalicylic acid. See *Aspirin*.  
 Acute Infarction Ramipril Efficacy (AIRE) trial, 161  
 Adenosine, 224, 274, 385  
     contraindications, 234-235  
     coronary artery disease detection with, 229-231  
     coronary artery disease risk stratification with, post  
         myocardial infarction, 239-240  
         pre-cardiovascular surgery, 238  
     hemodynamic effects of, 227  
     increased lung uptake with, 232-233  
     left ventricular cavity dilation with, 232-233  
     pharmacologic vasodilation with, mechanisms of, 224  
     potency of, 226  
     side effects of, 233-234  
     stress testing with, myocardial perfusion scintigraphy  
         and, 202-203  
         pharmacologic, 212  
     ST-segment depression with, 234  
 Adibendan, 67  
 Aging, neurohormonal activation effects of, 18-19  
     as risk factor, 2-3, 4-6  
 Aldosterone, 107-108  
 Aldosterone antagonists, 109-110  
 Ambulation, gradual, after Gianturco-Roubin coronary  
     stent procedure, 642  
 American College of Chest Physicians, Consensus  
     Conference on Antithrombotic Therapy,  
     recommendations (1992), 462, 474, 477, 480, 487  
 Aminophylline, 203  
 Amiodarone, 127-129  
 AMIS (Aspirin Myocardial Infarction Study Research  
     Group) study, 455-456  
 Amrinone, 64, 65, 67-68, 87  
 Anesthesia, general, in percutaneous cardiopulmonary  
     bypass support, 552-553  
 Aneurysm, left ventricular, systemic embolism with,  
     therapy for, 482  
 Angina pectoris, exertional, patient evaluation for,  
     myocardial perfusion scintigraphy for, 271  
     unstable, myocardial perfusion scintigraphy analysis  
         of, 257-258  
         patient identification and, 257-258  
         risk stratification from, 283  
 Angiography, coronary, percutaneous transluminal,  
     restenosis after, 651  
     during high-speed rotational ablation, adverse se-  
         quela, 607-608  
     iliofemoral, contraindications, 546  
     in percutaneous cardiopulmonary bypass support,  
         545  
     quantitative, in Palmaz-Schatz coronary stent treat-  
         ment analysis, 653-655  
     in Strecker stent treatment analysis, 681-682  
     in Wallstent treatment analysis, 693, 694, 695  
 radionuclide, exercise testing and, 192-193  
     first-pass, 189, **359-372**  
         advantages of, 359-361  
         camera and computer requirements for, 361-362  
         coronary artery disease detection with, 365-366,  
             387  
         coronary artery disease prognosis and, 366-367  
         gated, 364-365  
         history of, 359  
         perfusion/function imaging with, chronic pulmo-  
             nary disease and, 369  
         congenital heart disease and, 369  
         rationale for, 367-368  
         valvular heart disease and, 368-369  
         results of, 362-364

- Angioplasty, balloon for, with Gianturco-Roubin coronary stent, 636
- coronary, excimer laser, 585-593
- background, 585
  - clinical results, 588-590
    - with aorto-ostial stenoses, 589
    - with long lesions, 590
    - with saphenous vein graft stenoses, 588-589
    - with total occlusions, 589-590
  - complications, 590-591
    - coronary artery dissection, 590
    - coronary artery perforation, 590
    - coronary artery spasm, 590-591
    - restenosis, 591
  - future directions, 591-592
  - technique, 585-588
    - generators of, 585
    - guide catheters for, 585-586
    - guidewires for, 586
    - laser catheters for, 586-588
- percutaneous transluminal, 633-634, 709
- abrupt closure following, 519-527
    - antiplatelet agents for, 519-521
    - antithrombin agents for, 521-525
    - coronary artery stenting for, 526-527
    - thrombolytic agents for, 525-526
    - tissue factor for, 525
  - anticoagulant agents with, 517-535
  - antiplatelet agents with, 517-535
    - background, 517-519, 543, 595, 651, 699
    - evaluation following, greater than 6-month, 381
    - immediate, 375-377
    - less than 6-month, 377-381
  - PET imaging studies of coronary flow in, 309-311
  - radionuclide ventriculography for, 381
  - failed, Palmaz-Schatz stent for, 656-657
  - Strecker stent for, 683-684
  - Wiktor coronary stent for, 665, 667-668, 669-671
  - intracoronary thrombus with, 574-575
  - limitations of, 611
  - myocardial infarction management with. See under *Myocardial infarction*.
  - patient selection for, 374-375
    - radionuclide techniques in, 373-383
      - background, 373-374
    - restenosis following, 527-530
    - versus Rotablator system treatment, 605-607
    - technique for, 547
    - thrombosis formation after, 517-518
  - laser, for acute myocardial infarction, 567
  - primary, acute myocardial infarction managed with, 562-566
    - defined, 562
- Angioscopy, coronary percutaneous, 616-617
- Angiotensin-converting enzyme (ACE) inhibitors, 12, 87, 88-91, 98
- aldosterone antagonists and, mortality and, 109-110
  - angiotensin II receptor antagonists and, 110
  - cellular effects of, 16-17
  - diuretic agents versus, 105-106
  - diuretic therapy and, 47
  - hemodynamic effects of, 15
  - renin-angiotensin system blockade by, 101-105
  - research on, 105-107
  - ventricular arrhythmias and, 124-125
- Angiotensin II, 107-108
- cellular effects of, 15-17
  - ventricular remodeling role of, 12
- Angiotensin II receptor antagonists, 110
- Ankle-arm index, Doppler sonographic, 677
- Annexin V, 434
- Antiarrhythmic agents, ventricular arrhythmias and, 123
- Anticoagulant agents. See also specific agents.
- for deep venous thrombosis therapy, alone, 512
  - with cancer, 513
  - with inferior vena caval interruption, 513-514
  - in pregnancy, 513
  - for isolated calf vein thrombosis therapy, 513
  - for myocardial infarction, evolving, American College of Chest Physicians recommendations, 474
  - ancillary trials, 472-473
  - Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis, 471-472
  - Dutch Sixty Plus Reinfarction Study, 468-469
  - EPSIM trial, 469-470
  - German-Austrian Myocardial Infarction Study, 468
  - Italian Study Group trial, 470
  - for systemic embolism prevention, 479-481
  - trials, meta-analysis of, 467-468
  - Warfarin Reinfarction Study, 470-471
- post, 451-476
- Bronx Municipal Hospital Study, short-term therapy, 466
  - early trials, 462-463
  - International Anticoagulant Review Group 1970 Collaborative Analysis, 465-466
  - Medical Research Council study, long-term therapy, 463-464
  - short-term therapy, 464-465
  - Veterans Administration Cooperative Study, long-term therapy, 464
  - short-term therapy, 466-467
- oral, 405-406, 471-472, 474, 477
- for systemic embolism prevention, with atrial fibrillation, 502-503
    - with cardiac tumors, 483
    - with dilated cardiomyopathy, 482-483
    - with left ventricular aneurysm, 482
    - with prosthetic heart valve, 487-493
    - limitations, 490
  - with percutaneous transluminal coronary angioplasty, 517-535
  - pharmacology of, 421-423, 428-434
- Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis trial, 471-472
- Anticoagulation therapy, with circulatory assist devices, 145-146, 147, 148, 152
- Antimyosin antibodies, radiolabeled, infarct-avid imaging with, clinical applications of, 296-298
- scintigraphic principles of, 291-293
- technical aspects of, 293-294
- Antiplatelet agents, 474. See also specific agents.
- for drug delivery system, 708
  - with myocardial infarction, evolving, for systemic embolism prevention, 481-482
  - post, 451-476
  - after percutaneous transluminal coronary angioplasty, for abrupt closure, 519-521
  - for restenosis prevention, clinical trials of, 528-530
  - after prosthetic heart valve replacement, for systemic embolism prevention, 487-492
  - timing of administration, 458-459
- Antiplatelet Trialists' Collaboration I, 444, 460-461
- Antiplatelet Trialists' Collaboration II, 445-446, 461-462
- Antiproliferative agents, for drug delivery system, 708
- Antisense technology, 708
- Antistatin, 407, 525

- Antithrombin agents, for drug delivery system, 708
- Antithrombotic agents, 405-407. See also specific agents.  
with atrial fibrillation, clinical trials, 497-502  
coagulation by, inhibitors of, natural, 407  
factor Xa inhibitors, 407  
heparin. See *Heparin*.  
oral anticoagulants. See *Anticoagulant agents, oral*.  
with percutaneous transluminal coronary angioplasty,  
for abrupt closure following, 521-525  
for restenosis prevention, clinical trials, 530  
pharmacology of, 411-442  
background, 411-412  
for systemic embolism prevention, with cardiac tumors, 483  
with dilated cardiomyopathy, 482-483  
in high-risk patients, 479-483  
with left ventricular aneurysm, 482  
for systemic embolus prevention, with atrial fibrillation, trial results, 502  
thrombin inhibitors. See *Hirudin*; *Hirulog*; *Nonhirudin peptide*.
- Anturane. See *Sulfinpyrazone*.
- Anturane Reinfarction Italian Study (ARIS), 458
- Anturane Reinfarction Trial (ART) Research Group study, 457-458
- Aorta, distal abdominal, Strecker stent treatment of, discussion, 679-680  
patient and methods, 676-677  
results, 677-679
- Argatroban, 407, 431  
after percutaneous transluminal coronary angioplasty, 524
- Arginine vasopressin, 13
- Argipidine, 407
- ARIS (Anturane Reinfarction Italian Study), 458
- Arrhythmia, ventricular. See *Ventricular arrhythmias*.
- ART (Anturane Reinfarction Trial Research Group) study, 457-458
- Artery, coronary, ablation of. See *Catheter, rotablator*.  
abrupt closure of, emergency bypass grafting for, 633  
incidence of, 631-632  
intracoronary thrombus and, 574  
management of, 633  
mechanisms of, 632  
metallic stents to treat, 700-701  
pathophysiologic mechanisms of, 718-719  
percutaneous cardiopulmonary bypass support and, 551  
after percutaneous transluminal coronary angiography, 699-700  
after percutaneous transluminal coronary angioplasty, limitations, 611  
Palmaz-Schatz stent for, emergency use, 656-657  
stenting for, 526-527  
percutaneous transluminal coronary angioplasty and, 595  
polymeric endoluminal paving and, 716, 718-719  
risks of, 631-632  
Strecker stent treatment of, 683  
therapeutic thrombolysis for, 575-577  
intracoronary stents and, 578-579  
treatment possibilities for, 543  
acute closure of. See *Artery, coronary, abrupt closure of*.  
bypass grafting of, emergency, 633  
disease of. See *Coronary artery disease*.  
dissection, as excimer laser treatment complication, 590, 591  
long lesions of, excimer laser treatment of, 590  
low-speed rotational angioplasty to reopen, 625  
Rotablator system treatment of, 604  
versus percutaneous transluminal coronary angioplasty, 605-606  
native, Palmaz-Schatz intracoronary stent, elective use, BENESTENT trial, 655  
STRESS trial, 653-655  
Wallstent treatment of, 693  
noncoronary stent use, 657-658  
perforation, as excimer laser treatment complication, 590  
restenosis, after excimer laser treatment, 591  
spasm, as excimer laser treatment complication, 590-591  
stenting, for abrupt closure after percutaneous transluminal coronary angioplasty, 526-527  
threatened closure of, incidence of, 631-632  
management of, 633  
mechanisms of, 632  
Palmaz-Schatz stent use with, 656  
risks of, 631-632  
total occlusion of, excimer laser treatment of, 589-590  
reopening with low-speed rotational angioplasty. See *Catheter, low-speed rotational angioplasty*.  
therapeutic thrombolysis for, 577-578  
intracoronary stents and, 578-579  
femoropopliteal, Strecker stent treatment of, discussion, 679-680  
patients and methods, 676-677  
results, 677-679  
iliac, long lesions of, new stent indication, 680  
Strecker stent treatment of, discussion, 679-680  
patients and methods, 676-677  
results, 677  
renal, Strecker stent treatment of, complications, 681
- Asasantine, 457
- Ashkenazi Jews, factor XI deficiency in, 404
- Aspirin, 400, 427-428, 474, 574, 575  
for cardiovascular disease, primary prevention, 443-450  
for deep venous thrombosis prophylaxis, 510  
ECSC Trial and, 561  
Gianturco-Roubin coronary stent procedure and, 638, 639  
history, 443  
mechanism of, 443  
for myocardial infarction, evolving, Dutch Heart Foundation studies, 460  
International Studies of Infarct Survival, 459  
second, 459-460  
overview studies, American College of Chest Physicians Consensus Conference, third, 462  
Antiplatelet Trialists' Collaboration I, 460-461  
Antiplatelet Trialists' Collaboration II, 461-462  
randomized trials with, 446, 448  
post, for systemic embolism prevention, 481  
primary prevention, randomized trials with, 446-447, 448-449  
secondary prevention, Aspirin Myocardial Infarction Study Research Group trial, 455-456  
Boston Collaborative Drug Surveillance Group trial, 453  
Coronary Drug Project Research Group trial, 454  
German-Austrian Myocardial Infarction Study, 455  
Medical Research Council Epidemiology Unit, Cardiff, Cardiff I, 453-454  
Cardiff II, 454-455

Aspirin (*Continued*)

- Persantine and Aspirin in Coronary Heart Disease study, I, 456
  - II, 457
- randomized trials with, 444-446, 448
  - Society for Clinical Trials, 456-457
  - trials for, 451-457
- observational studies with, 443-444
  - with percutaneous transluminal coronary angioplasty, 520
    - for restenosis prevention, 528-529
- percutaneous transluminal coronary angioplasty and, 547
  - pharmacology of, 412-416
  - side effects of, 447-448
- Strecker stent treatment of distal abdominal aorta and iliac and femoropopliteal arteries and, 677
  - subacute coronary stent thrombus formation and, 658
    - for systemic embolism prevention, with atrial fibrillation, clinical trial results, 498-502
      - with prosthetic heart valve, 489-492
- Aspirin Myocardial Infarction Study (AMIS) Research Group study, 455-456
- Atherectomy, for acute myocardial infarction, 566-567
  - coronary, transluminal extraction, 611-622
    - background, 611
    - catheter design, 612
    - clinical results, 612-616
    - developmental studies, 611-612
    - indications for, 617
      - in acute myocardial infarction, 620
    - adjunctive therapies and, 619-620
    - saphenous vein bypass grafts, 617-619
    - mechanisms of action, per coronary angiography, 616-617
      - per intravascular ultrasound, 616-617
    - patient selection, 612
    - protocol, 612
    - restenosis with, 616
  - directional, contraindications, 620
- Atrial natriuretic peptide, 13-14, 15
  - cellular effects, 16-17
  - plasma levels of, mortality and, 32-33
  - prognostic effects, 17-18
- Attenuation, correction of, technetium-99m sestamibi for, 216
- BAATAF (Boston Area Anticoagulation Trial for Atrial Fibrillation), 499-500
- Bailout. See Angioplasty, coronary, percutaneous transluminal, failed.
- Balloon pump, 543
  - intra-aortic, placement, in percutaneous cardiopulmonary bypass support, 554
  - versus percutaneous cardiopulmonary bypass support, 551
- Basel Antiarrhythmic Study of Infarct Survival (BASIS), 128
- BATO. See Boronic acid adduct of technetium dioxide (BATO) compounds.
- Bayes' theorem, 207
- BENESTENT Trial, 655, 700, 717
- Bernard-Soulier syndrome, 399, 424
- Beta-blocker Evaluation of Survival Trial (BEST), 138
- Beta-blocker Heart Attack Trial (BHAT), digitalis data, 58-59
  - ventricular arrhythmias and, 127
- Beta-blockers, 133-142
  - adrenergic balance and, 133-134
  - background, 133
  - beneficial effects, 134-136
  - mechanisms of action, possible, 136-137
  - titration of, 138
    - treatment choices, 137-138
  - ventricular arrhythmias and, 126-127
- Bias, referral, thallium-201 imaging sensitivity and specificity and, 205
- Bifurcation, aortic, long lesions of, new stent indication, 680
  - Strecker stent treatment of, 676
- Biomedicus pump, 144-146, 150
- Bird's nest filter for inferior vena caval interruption treatment, 513-514
- Bishydroxycoumarin, 464
- Blood flow, coronary. See Coronary blood flow.
- Boot, intermittent pneumatic compression, 508
- Boronic acid adduct of technetium dioxide (BATO)
  - compounds, 169, 170, 188
- Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF), 499-500
- Boston Collaborative Drug Surveillance Group trial, 451-453
- Bradycardia, high-speed rotational ablation and, 607
- Bronx Municipal Hospital study, of anticoagulant agents post myocardial infarction, 466
  - systemic embolism and, 472-473
  - venous thromboembolism and, 473
- Bucindolol, 137
- Bypass support, percutaneous cardiopulmonary, 543-557
  - adjunctive procedures during, 551-554
  - analysis of, 550-551
  - background, 543-544
  - circulatory support devices for, 554-555
  - complications with, 550-551
  - contraindications, 545
  - emergency, therapy in, 547
  - patient observations, 550
  - prophylactic versus standby, 544
  - technique, 545-547
    - cannulation, 545-546
    - contraindications, 546
    - iliofemoral angiography, 545
    - initiation of, 546-547
    - portable system, 546
    - termination of, 547-548
- Bypass surgery, emergency, intracoronary thrombus and, 574
- Bypass system, heart, percutaneous partial left-sided, in percutaneous cardiopulmonary bypass support, 555
- Calcium antagonist, with Gianturco-Roubin coronary stent procedure, 638
- Calcium channel blockers, 87, 93
- Canadian Atrial Fibrillation Anticoagulation trial, 499-500
- Cancer, deep venous thrombosis therapy with, 513
- Cannulation, in percutaneous cardiopulmonary bypass support, 545-546
  - complications due to, 550-551
  - removal, in percutaneous cardiopulmonary bypass support, 548
- Captopril, 160-161
  - FDA approval of, 107
  - nitrate tolerance and, 81
  - renal vasoconstrictor effects, 15

- Captopril/digoxin study, 124  
 mortality and, 26  
 angiotensin-converting enzyme inhibitor effects on, implications of, 105  
 exercise duration and, 28  
 ventricular arrhythmias and, 117-118, 124
- Cardiac. *See* Heart.
- Cardiac arrest, 550  
 cardiopulmonary bypass support termination and, 548  
 contraindication to iliofemoral angiography, 546
- Cardiac Arrhythmias Suppression Trial (CAST), 122  
 beta-blockers and, 134
- Cardiff I trial, 453-454  
 Cardiff II trial, 454-455
- Cardiomyopathy, antimosin antibody imaging and, 299  
 dilated, systemic embolism with, therapy for, 482-483  
 hypertrophic, blood flow measurements of, PET imaging with, 311
- Cardiomyoplasty, dynamic, 149
- Cardiotoxicity, doxorubicin-induced, antimosin antibody imaging and, 299
- Cardioversion, electrical, systemic embolism following, 501  
 in systemic embolism prevention, 497
- CardioWest Biventricular Prosthesis, 149
- Carvedilol, 137
- Catecholamines, 136-137
- Catheter, balloon, channeled, 707  
 double, 707  
 iontophoretic, 707  
 microporous, 707  
 perfusion angioplasty with, 633-634  
 porous, 707  
 stented porous, 707
- central venous, chronic indwelling, deep venous thrombosis prophylaxis with, 510  
 deep venous thrombosis therapy with, 510  
 for gel polymer paving, 725  
 guide, for excimer laser, 585-586  
 for Gianturco-Roubin coronary stent, 636  
 hydrogel, 707  
 laser, for excimer laser, 586-588  
 for local drug delivery by polymeric stent, 706-708  
 low-speed rotational angioplasty, 623-629  
 background, 623  
 complications, 625-627, 628  
 description, 623-624  
 patients for, 624  
 procedure, 624-625  
 results with, 627-628  
 long-term, 627  
 short-term, 625  
 monitoring, pulmonary artery, in percutaneous cardiopulmonary bypass support, 552  
 perfusion, selection and placement, for therapeutic thrombolysis, 580
- rotablator, 595-610  
 ablation, high-speed rotational, analysis of, 597-600  
 issues unique to, 607-608  
 background, 595  
 clinical experience with, 600-601  
 multicenter, 601  
 design characteristics, 596-597  
 future trends, 608-609  
 versus percutaneous transluminal coronary angioplasty, 605-607  
 physical principles, 596-597  
 procedure, 601-602  
 complications with, 602-603  
 successes with, 602-603  
 results with, 603-605  
 system description, 595-596  
 sleeve, porous, 707  
 for solid polymer paving, 721-722  
 transluminal extraction-endarterectomy. *See also* Atherectomy, coronary, transluminal extraction.  
 clinical results with, 566-567, 612-616  
 design, 612  
 developmental studies, 611-612  
 indications for, 617-620  
 in acute myocardial infarction, 620  
 adjunctive therapies, 619-620  
 saphenous vein bypass grafts, 617-619  
 mechanisms of action, per coronary angiography, 616-617  
 per intravascular ultrasound, 616-617  
 patient selection, 612  
 protocol, 612  
 restenosis with, 616
- CDO-BOH, myocardial kinetics with, cell culture studies of, 170-171
- CDO-MEB. *See* Teboroxime.
- CDP-A (Coronary Drug Project Research Group) trial, 454
- Cell injury, evidence of, 177  
 induction of, 177, 178
- Centrimed pump, 146, 150
- Cerebral Embolism Study Group trial, 500-501
- Cicaprost, 420
- Cineangiography, radionuclide (RNCA), coronary artery disease assessment with, 333-357  
 background of, 333  
 diagnostic applications of, 336-340  
 future directions of, 350-352  
 history of, 333-336  
 prognostication of, 340-350  
 equilibrium, 335  
 pharmacologic interventions with, assessment of, 349-350
- Circulation, pulmonary, radionuclide transit time in, first-pass radionuclide angiography and, 363
- Circulatory assist devices, 143-153  
 background, 143  
 description, 143-149  
 nonpulsatile, 144-146  
 pulsatile, 146-149  
 future directions, 152  
 implantation decisions, 152  
 patient selection, 143  
 support indications, 149-152
- Cleveland Clinic/Mayo/Thoraxcenter bioabsorbable stent, 703
- Clopidogrel, 420
- Closure, acute. *See* Artery, coronary, abrupt closure of.
- Coagulation factor activation, 400-405  
 initiation, 401-402  
 thrombin generation in, accelerated, 402-403  
 inhibition of, 403-405
- Coagulation inhibitors, natural, 407
- Cooperative North Scandinavian Enalapril Survival study (CONSENSUS), 18  
 angiotensin-converting enzyme inhibitor effects, 12, 90-91  
 on mortality, 101-105, 108-109  
 implications of, 105-107  
 isosorbide dinitrate survival data, 76  
 neurohormonal activation data, 17  
 prognostic data, 17-18  
 sudden cardiac death, 116  
 ventricular arrhythmias and, 117, 124



- Copenhagen AFASAK trial, 498, 499-500  
 Copenhagen AFASAF-2 trial, 502  
 Copolymer, defined, 701  
 Coronary artery bypass grafting, 374  
 Coronary artery disease. *See also Angina; Myocardial infarction.*  
   anatomic vs physiologic, 272  
   detection of, first-pass radionuclide angiography for, 365-366  
   imaging methods for, choice of, 386-387  
   percutaneous transluminal coronary angioplasty patients and, 373-374, 374-375  
   PET imaging for, 306-307  
   pharmacologic stressors for, 229-232. *See also specific agents.*  
   technetium-99m sestamibi for, 191-192  
   vs thallium-201, planar imaging and, 213-214  
   SPECT imaging and, 214-215  
   thallium-201 for, 207-208  
     individual artery imaging with, 208-209  
     myocardial perfusion scintigraphy with, 208-209  
     pharmacologic vs exercise stress testing and, 207  
     planar imaging analysis and, 203-205  
     referral bias and, 205  
     severe, extensive disease analysis with, 209-212  
     SPECT imaging analysis and, 205-207  
   evaluation of, radionuclide techniques for, choice of, 385-389  
   functional assessment of, imaging methods for, choice of, 387  
   left main, detection of, 208, 209-210  
   myocardial revascularization in, 317-318  
   prognosis of, first-pass radionuclide angiography for, 366-367  
     imaging methods for, 387  
     myocardial perfusion scintigraphy for, 271-287  
     patient evaluation in, 271-272  
   radionuclide cineangiographic assessment of, 333-357  
     background of, 333  
     diagnostic studies of, 336-340  
     future directions of, 350-352  
     history of, 333-336  
     prognostication with, 340-350  
   risk stratification of, pharmacologic stress testing for, 235  
     post myocardial infarction assessment with, 238-240  
     pre-cardiovascular surgery assessment, 235-238  
   stable, prognosis of, with myocardial perfusion scintigraphy for, normal exercise test results, 273  
     normal nonexercise test results, 274  
     positive exercise test results, 272-273  
     positive nonexercise test results, 274  
     other radionuclide markers for, 274-276  
 Coronary blood flow, assessment, with PET imaging, 303-304, 303-315  
   markers of, noninvasive. *See Perfusion agents, radiolabeled, physiologic properties of.*  
   PET imaging of, coronary artery disease and, 306-307  
   emerging techniques for, 309  
   myocardium viability studies and, 307-309  
   normal human myocardium studies and, 304-306  
   regional, quantitative assessment of, PET imaging for, 309-312  
   regulation of, coronary flow reserve and, 223-224  
 Coronary Drug Project Research Group trial, 454  
 Coumadin, with Gianturco-Roubin coronary stent procedure, 639  
 Coumarins, pharmacology of, 421-422  
 Creatine kinase, as evidence of cell injury, 177  
 Creatine kinase-MB enzyme studies, myocardial infarction diagnosis with, 289  
 Crone-Renkin capillary permeability-surface area product, 172  
 Cutting, differential, in high-speed rotational ablation, 597  
 Cyanide, 177  
   cell injury induced by, 178  
 Cytochrome C oxidase inhibitors, 187  
 Degradation, heterogeneous (surface), of bioabsorbable polymers, 703  
   homogeneous (bulk), of bioabsorbable polymers, 703  
 Dexamethasone, local delivery of, 708  
 Dextran, 547  
   with Gianturco-Roubin coronary stent procedure, 639  
   low molecular weight, for subacute coronary stent thrombus formation, 658  
   for subacute coronary stent thrombus formation, elimination of, 661  
 Diabetes mellitus, 4-6  
 Diastolic dysfunction, 10, 26  
 Dicumarol, 462  
 Digitalis glycosides, 51-61, 134  
   cardiac actions of, 52  
   clinical trials of, past, 52-56  
   Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin, 56-57  
   Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme, 56-57  
   controversy about, 51-52  
   dose-response of, 59  
   survival effects of, 57-59  
   ventricular arrhythmias and, 123  
 Digoxin, 10, 51  
   favorable effects of, 17  
 Dipyridamole, 224, 274, 385, 400  
   and aspirin, 444-445  
   after percutaneous transluminal coronary angioplasty, 520  
   contraindications, 234-235  
   coronary artery dilation with, mechanisms of, 225  
   coronary artery disease detection with, 228-229  
   coronary artery disease risk stratification with, 235  
     post myocardial infarction, 238-239  
     pre-cardiovascular surgery and, 235-238  
   with Gianturco-Roubin coronary stent procedure, 639  
   hemodynamic effects of, 226-227  
   increased lung uptake with, 232-233  
   left ventricular cavity dilation with, 232-233  
   for myocardial infarction, secondary prevention, trials for, 451-457  
   myocardial perfusion scintigraphy and, stress testing with, 202-203, 207  
   pharmacologic, 212  
   pharmacology of, 416-419  
   potency of, 225-226  
   radionuclide cineangiography with, 339  
   side effects of, 233  
   ST-segment depression with, 234  
   for subacute coronary stent thrombus formation, elimination of, 661  
   subacute coronary stent thrombus formation and, 658-659  
   for systemic embolism prevention with prosthetic heart valve, 490  
 Disopyramide, 126  
 Dissection of coronary artery. *See under Artery.*

- Diuretic therapy, 9, 47-48  
 angiotensin-converting enzyme inhibitors versus, 105-106  
 electrolyte imbalance and, 37-50  
   sodium retention and, 37-39  
   neurohormonal activation by, 44-45  
 pharmacokinetics, 39-43  
   in congestive heart failure, 43-44  
   loop diuretics and, 39-40  
   potassium-sparing diuretics and, 43  
   thiazides and, 40-43  
 resistance to, 46-47
- Dobutamine, 64-66, 274, 385  
 contraindications, 235  
 coronary artery dilation with, mechanisms of, 225  
 coronary artery disease detection with, 231-232  
 coronary artery disease risk stratification with, before cardiovascular surgery, 238  
   after myocardial infarction, 240  
 hemodynamic effects of, 227-228  
 ischemia induced by, 224  
 potency of, 226  
 radionuclide cineangiography with, 339-340  
 side effects of, 234  
 ST-segment depression with, 234
- Dopamine, 64, 67, 87
- Dopexamine, 64-66
- Doppler sonographic ankle-arm index, 677
- Doughnut pattern, 296
- Drug delivery system. *See also Stent, polymeric.*  
 local, drugs available for, 708
- Dual-isotope imaging, 196, 213  
 at rest, 216  
 with SPECT, and rest thallium-201/stress technetium-99m sestamibi, 261-270  
   clinical implications, 269-270  
   coronary artery disease detection, 263-265  
   cost considerations, 268-269  
   defect reversibility detection, 265-266  
   image quality, 266-268  
   protocols, advantages, 268  
     separate acquisition, 262-263  
     simultaneous acquisition, 262  
   quantitative analysis, 266  
   with SPECT, and rest thallium-201/stress technetium-99m sestamibi, protocols, separate acquisition, advantages of, 268  
   with technetium-99m sestamibi, 216
- Duke bioabsorbable stent, 705
- Dutch Heart Foundation Studies, 460
- Dutch Sixty Plus Reinfarction Study, 468-469
- Echocardiography, contrast, myocardial infarction  
 diagnosis with, 289-290  
   myocardial viability assessment with, 328-329  
 for left ventricular thrombosis detection, 478  
 transesophageal, in percutaneous cardiopulmonary bypass support, 552
- Edema, 37-39
- Ejection fraction, ventricular, mortality and, 29-30
- Electrocardiogram, abnormalities in, 5  
 gated, coronary artery disease detection with, 386  
 myocardial infarction diagnosis with, 289  
   limitations of, 294  
   myocardium at risk and, 248  
   signal-averaged, and heart rate variability, 119-120
- Electrolyte imbalance, 45. *See also under Diuretic therapy.*  
 supplementation for, 45-46
- ventricular arrhythmias and, 123
- Embolism, paradoxical, 505, 514-515  
 pulmonary, 505  
 systemic, prevention, with abnormal ventricular function, 477-485  
   antithrombotic therapy for, 479-483  
   background, 477  
   primary and secondary, 477-479  
   with atrial fibrillation, 495-504  
     anticoagulant agents for, oral, 502-503  
     with antithrombotic agents, 497-502  
     background, 495-496  
     with cardioversion and sinus rhythm maintenance, 497  
     prognosis with, 496-497  
     trial results, 502  
   after electrical cardioversion, 501  
   with myocardial infarction, anticoagulant agents for, 472-473  
   primary, 477-479  
   with prosthetic heart valve, 487-493  
   secondary, 477-479  
 venous, prevention, with myocardial infarction, anticoagulant agents, 473
- Embolization. *See Embolism.*
- Enalapril. *See also Cooperative North Scandinavian Enalapril Survival study (CONSENSUS); Veterans Administration Heart Failure Study.*  
 FDA approval of, 107  
 renal vasoconstrictor effects, 15
- Endothelial-derived relaxation factor, 400, 413, 417
- Endothelin, 12-13, 15
- Endothelium-derived relaxing factor, 14-15
- Enoxaparin, 509-510
- Enoximone, 65, 67-68
- EPIC (Evaluation of c7E3 in the Prevention of Ischemic Complications) trial, 521
- EPSIM trial, 469-470
- European Atrial Fibrillation Trial, 501-502
- European Cooperative Study Group (ECSCG) Trial, 561
- Evaluation of c7E3 in the Prevention of Ischemic Complications (EPIC) trial, 521
- Evaluation of Losartan in the Elderly Trial (ELITE), 110
- Exercise, stress. *See Stress testing, exercise.*  
 therapeutic, radionuclide cineangiographic assessment of, 349
- Exercise tolerance, beta-blockers and, 135  
 as functional capacity measure, 28  
 nitrate effects on, 74
- Extracorporeal membrane oxygenation, 145-146, 150-151
- Factor II, 421
- Factor V, 402, 404
- Factor VII, 401-402, 421
- Factor VIIa, 401-402
- Factor VIIa-tissue factor complex, 434
- Factor VIII, 402-403, 404
- Factor VIIIa, 402-403
- Factor IX, 421
- Factor X, 401-402, 403, 421, 521
- Factor Xa, 401-402, 402-403, 421, 433-434  
 inhibitors of, 407
- Factor XI, 404-405
- Factor XIIa, 405
- Factor XIII, 432
- Fenoldopam, 64, 67
- Fibrillation, atrial, lone, 497

## Fibrillation (Continued)

- risk factors for, 496
- systemic embolism and, background, 495-496
- prevention, 495-504
  - with antithrombotic agents, 497-503
  - with cardioversion and sinus rhythm maintenance, 497
  - with oral anticoagulant agents, 502-503
  - prognosis with, 496-497
- Fibrin, 405
- Fibrinogen, 400, 404, 405
- Fibrinolysis, 405
  - aspirin in, 415
- First National Health and Nutrition Examination Survey (NHANES-1), 2-3, 7
- Fish oil, 529
- Flex-stent. *See* Stent, coronary, Gianturco-Roubin.
- Flosequinan, 87, 94
- Flosool, 555
- Fourier-phase analysis, radionuclide cineangiography and, 339
- Framingham study, 2-3, 4-6, 6-7
  - mortality data, 25
- Fraxiparine, 509
- French Canadians, factor XI deficiency in, 404
- Friction, orthogonal displacement of, in high-speed rotational ablation, 597
- Functional capacity, mortality and, 27-28
- Function imaging, myocardial perfusion scintigraphy for, first-pass radionuclide angiography and, 367-368
- Furifosmin (Q-12), 195
- Furosemide, 44

## GAMIS (German-Austrian Myocardial Infarction Study), 455, 468

## Gamma-camera imaging, 181

## multicrystal, first-pass radionuclide angiography with, 361

## Gated imaging, 213, 385

- background of, 334-335
- coronary artery disease detection with, 386
- first-pass radionuclide angiography with, 364-365
- technetium-labeled perfusion agents with, 193
- technetium-99m sestamibi as, 216

## Gene therapy, 434

## local delivery systems for, 708-709

## German-Austrian Myocardial Infarction Study, 455, 468

## GISSI-I Study, 565

## GISSI-II Study, 565-566

## Glanzmann's thrombasthenia, 400, 425

## Glucose utilization rates, PET imaging for analysis of, 305-306

## Glycoprotein Ib, 399

## Glycoprotein IIB/IIIA receptor antagonists of platelets, pharmacology of, 424-427

Glycosides. *See* Digitalis glycosides; Inotropic agents, nonglycoside.

## Gold-195m, 361

## Goldman criteria, 280

## Gothenberg study, 2, 5-6

## Greenfield filter for inferior vena caval interruption treatment, 513-514

## Growth factors, 527, 699-700, 718

## Guidewire, for excimer laser, 586

## for Gianturco-Roubin coronary stent, 636

## Haementeria officinalis, 407

## Heart, wall motion of, first-pass radionuclide angiographic measurements of, 362

Heart disease. *See also* Angina; Coronary artery disease; Myocardial infarction.

## congenital, first-pass radionuclide angiographic imaging of, 369

## valvular, first-pass radionuclide angiographic imaging of, 368-369

Heart failure, neurohumoral aspects of. *See*

## Neurohumoral aspects of heart failure.

## HeartMate pump, 148

## Heart rate variability, signal-averaged

## electrocardiography and, 119-120

## Heart transplant, antimyosin antibody imaging and, 298

## nonrejecting, blood flow measurements of, PET imaging for, 311

## Heart tumor, systemic embolism with, therapy for, 483

## Heart valve, prosthetic, mechanical, 488-490

## antiplatelet therapy with, 481

## thromboembolism prevention with, 487-493

## tissue, 488

## Hematocrit level, 5

## Hemocompatibility, 703

## of biodegradable thermoplastics, in polymer paving, 727-728

## Hemodynamic studies, myocardial infarction diagnosis with, 289

## Hemodynamic system, congestive heart failure and, 9

## digitalis glycoside action on, 52

## nitrate effects on, 73-74

## parameters of, as predictors of survival, 28-29

## Hemopump, 146, 151, 152

## in percutaneous cardiopulmonary bypass support, 555

## Hemostasis, 411-412

## antithrombotic agents and, 405-407

## coagulation factor activation, 400-405

## defined, 399

## fibrinogen, fibrin, and fibrinolysis in, 405

## mechanisms, 399-476

## platelet deposition and recruitment, 399-400

Heparin, 405-406, 428, 466, 470, 574, 575. *See*

## Anticoagulation therapy.

## coating, on Palmaz-Schatz stent, 660-661, 708

## for deep venous thrombosis, 473, 512

## with cancer, 513

## during pregnancy, 513

## in European Cooperative Study Group Trial, 561

## for Gianturco-Roubin coronary stent procedure, 639

## low molecular weight, 405-406

## for deep venous thrombosis prophylaxis, 509-510

## for deep venous thrombosis therapy, 512-513

## for restenosis prevention after percutaneous transluminal coronary angioplasty, 530

## after percutaneous transluminal coronary angioplasty, 521-523

## for restenosis prevention, 530

## pharmacology, 422-423

## stents releasing, 686

## for Strecker stent procedure in carotid artery, 684

## for Strecker stent treatment of distal abdominal aorta and iliac and femoropopliteal arteries, 677

## for subacute coronary stent thrombus formation, 658-659

## for systemic embolism prevention, after myocardial infarction, 480-481

## during myocardial infarction, 479

## with prosthetic heart valves, 487-488

## unfractionated low-dose, for deep venous thrombosis prophylaxis, 508-509



Heparin sulfate-antithrombin III system, 403-405

Hirudin, 406-407

derivatives of, 406-407

pharmacology of, 428-431

after percutaneous transluminal coronary angioplasty, 523-524

for restenosis, 528

pharmacology, 428-431

*Hirudo medicinalis*, 406

Hirulog, 406-407

after percutaneous transluminal coronary angioplasty, 523-524

pharmacology, 430

Histocompatibility, 703

Hospitalization trends, 3-4

Hydralazine, 87, 92-93, 95

with isosorbide dinitrate, 74-76, 76, 83

Hypertension, as risk factor, 4-6

Hypertrophy, left ventricular. *See* Left ventricular hypertrophy.

Ibopamine, 64, 67, 70

Iloprost, 420

Imaging modalities. *See* Angiocardiology, radionuclide, first-pass; Echocardiography; Gated imaging; PET imaging; Planar imaging; SPECT imaging.

Infarct-avid agents, antimyosin antibody, radiolabeled, clinical applications of, 296-298

in inflammatory myocardial conditions, 298-299

scintigraphy with, principles of, 291-293

technical aspects of, 293

background, 290

clinical applications, 294-298

pyrophosphate, technetium-99m, clinical applications, 294-296

scintigraphy with, principles of, 290-291

technical aspects, 293

scintigraphy with, principles of, 290-293

technical aspects, 293-294

Inotropic agents, nonglycoside, 63-72, 134

adrenergic, 64-67

background, 63-64

clinical indications, 70

nonadrenergic, 67-70

INR. *See* International normalized ratio.

Insufficiency, venous, treatment, 514

International Anticoagulant Review Group, of anticoagulant therapy post myocardial infarction, collaborative analysis, 465-466

International Multicentre Trial, 508-509

International normalized ratio, with anticoagulant therapy, 487-492, 488-492, 498, 501-503, 513

International Studies of Infarct Survival trial, 459

II, 459-460

Iodoacetate, 177

Iridium-191m, 361

Ischemia, during exercise stress, 224

myocardial, recurrent, ventricular arrhythmias and, 122-123

during pharmacologic stress, 224

radionuclide cineangiographic measurements of, prognostic value of, 340-345

resting, 387

ISDN. *See* Isosorbide dinitrate (ISDN).

Isomazole, 67, 69

Isonitriles, technetium-99m, 351

Isosorbide dinitrate (ISDN). *See* also Nitrates.

ejection fraction effects of, 76-77

exercise tolerance effects of, 74

hemodynamic effects of, 73-74

hydralazine and, 74-76, 76, 83, 103

survival effects of, 74-75

therapy limitations of, 77-82

Italian Study Group trial, 470

Kissing method, 676

Kringle region, 405

Kyoto University bioabsorbable stent, 703

Labetolol, 138

Lactate dehydrogenase, as evidence of cell injury, 177

Laser, excimer. *See* under Angioplasty.

Leech. *See* Hirudin.

Left ventricular dysfunction, and dilatation, causes of, 155-156

significance of, 156

systolic, angiotensin-converting enzyme inhibitors for, 101-105, 108-109

research results, 105-107

mortality effects of renin-angiotensin system blockade on, 101-114

renin-angiotensin system activation in, 108

Left ventricular hypertrophy, as risk factor, 5

Levodopa, 64, 67

Lisinopril, 107

Loop diuretic agents, 39-40, 46-47

Losartan, 110

Lungs, adenosine uptake by, 232-233

dipyridamole uptake by, 232-233

thallium-201 uptake by, 211, 274-275

Magnesium loss, with increased aldosterone production, 109-110

Magnum wire, 628

Manchester Comparative reagent. *See* Thromboplastin, human brain.

Map, polar, 304-305

Match, 298, 328

defined, 307

Medical Research Council Epidemiology Unit, Cardiff.

*See* Cardiff I trial; Cardiff II trial.

Medical Research Council trial, of anticoagulant agents for myocardial infarction, long-term therapy, 463-464

short-term therapy, 464-465

systemic embolism and, 472-473

venous thromboembolism and, 473

Meta-analysis, 451

Methoxyisobutyl isonitrile, technetium-99, 212

Metoprolol, 137, 138

Mexiletine, 126

Milrinone, 65, 67-68, 87, 93-94

Mismatch, 328

defined, 307

Misonidazole-18F, 181

Mortality, 1, 5-6, 87, 101, 133

predictors of, 25-35

background, 25-26

diastolic dysfunction and, 26

functional capacity and, 27-28

hemodynamic parameters and, 28-29

neurohormonal activation and, 32-33

Mortality (*Continued*)

systolic dysfunction and, 26-27

ventricular arrhythmias and, 30-32

ventricular ejection fraction and, 29-30

Multicenter Diltiazem Postinfarction Trial (MDPIT), 93

Multi-center Investigation of the Limitation of Infarct Size (MILIS), 58-59

Multiple indicator-dilution technique, 172

Myocardial infarction, acute. *See also Myocardial infarction, evolving.*

angioplasty for, primary, 562-566

defined, 562

in high-risk patients, 565-566

versus lytic agents, randomized trials of, 563-565

in lytic-ineligible patients, 565-566

interventional management strategies, 559-571

background, 559-560

cost considerations, 567-569

quality considerations, 567-568

in the 1990s, 567-569

interventional technologies for, 566-567

atherectomy, 566-567

intracoronary stents, 567

laser angioplasty, 567

intracoronary thrombus and, 574

risk with totally occluded vessels, 581

thrombolytic therapies for, percutaneous

transluminal coronary angioplasty after, 560-562

deferred versus elective, 562

immediate versus delayed, 560-561

rescue, 561

transluminal extraction-endarterectomy catheter with, 620

antithrombotic therapy, third ACCP Consensus Conference on, 474

diagnosis of, echocardiography for, 289-290

electrocardiogram for, 289

hemodynamic studies for, 289

radionuclide imaging techniques for, 289-290

ultrasonography for, 289

evolving. *See also Myocardial infarction, acute.*

anticoagulant agent trials, ancillary, 472-473

antiplatelet agent trials, 458-460

aspirin therapy trials, 446

systemic embolism with, anticoagulant therapy, 479-481

antiplatelet therapy, 481-482

antithrombotic therapy, 479-482

myocardial perfusion scintigraphy analysis of, 247-257

arterial patency and, 251-252

collateral flow to infarct zone and, 252-253

infarct size and, 249-250

models of, 253-255

lack of ST-segment elevation and, 255-257

myocardial salvage and, 250-251

myocardium at risk and, 247-249

size and, 249-250

non-Q-wave, 279

detection of, 294

nuclear imaging with infarct-avid agents. *See Infarct-avid agents.*

post, anticoagulant agents, 451-476

trials, Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis, 471-472

early, 462-467

EPSIM, 469-470

GAMIS, 468

Italian Study Group Trial, 470

meta-analyses of, 467-468

Sixty Plus Reinfarction Study, 468-469

Warfarin Reinfarction Study, 470-471

antiplatelet agents, 451-476

trials, long-term, aspirin and persantine, 451-457

sulfipyrazole, 457-458

aspirin trials, overviews of, 460-462

secondary prevention, 444-446

prognostication with antimyosin antibody imaging, radiolabeled, 297-298

prophylaxis, aspirin trials, 446-447

risk stratification following, 276-280

early after infarction, 279

non-Q-wave infarct and, 279

stress testing for, exercise, myocardial perfusion

scintigraphy and, 276-277

pharmacologic, 238-240

myocardial perfusion scintigraphy and, 277-279

after thrombolytic therapy, 279-280

technetium-labeled perfusion agent assessment of, 194

Myocardial infarction shock, circulatory assist devices for, 150-151

Myocardial perfusion agents. *See Perfusion agents, radiolabeled.*Myocardial perfusion imaging. *See Scintigraphy, myocardial perfusion.*

Myocarditis, antimyosin antibody imaging and, 298

diagnosis of, gold standard for, 299

ventricular arrhythmias secondary to, 123

Myocardium, hibernating, 318, 323, 349

inflammation of, nuclear imaging to detect, 298-299

match, 298, 307, 328

metabolism of, imaging of, 290

mismatch, 307, 328

necrosis of, nuclear imaging to detect, 289-298

background of, 289-290

infarct-avid agents for, 290-293

clinical applications of, 294-298

technical aspects of, 293-294

noninvasive blood flow studies in, PET imaging for, 303-304, 306, 309-312

perfusion scintigraphy of. *See Scintigraphy, myocardial perfusion.*

radiolabeled perfusion agent uptake by, cell culture studies of, 170-171

isolated heart model of, 171-173

in vivo models of, 173-177

revascularization of, 317-318

at risk, assessment of, myocardial perfusion scintigraphy in, 247-249

salvage of, myocardial perfusion scintigraphy in, 250-251

stunned, 150, 318

thallium-201 defects in, types of, 200

viability of, assessment of, 317-332

background of, 317-318

contrast echocardiography for, 328-329

imaging methods for, 387

PET imaging for, 307-309, 327-328

techniques for, 309

radiolabeled perfusion agents in, background of, 177

cell culture studies of, 177-178

isolated heart model studies of, 178

in vivo studies of, 178-181

radionuclide ventriculography in, 328

technetium-99m sestamibi imaging in, 326-327

thallium-201 imaging in, 318-326

Myxomas, 483

National Hospital Discharge Survey (NHDS), 3-4

- Neo-Synephrine, 546
- Neurohormonal system, activation, cellular effects, 15-17  
     by diuretic therapy, 44-45  
     hemodynamic effects, 15  
     mortality and, 32-33  
     antagonism of, benefits, beta-blockers and, 134  
     digitalis glycoside action on, 52
- Neurohumoral aspects of heart failure, 9-23  
     arginine vasopressin, 13  
     endothelin, 12-13  
     neurohormonal activation effects, 15-17  
     neurohumoral systems, 9-10  
     prognostic implications, 17-18  
     renin-angiotensin system, 11-12  
     sympathetic nervous system, 10-11  
     syndrome progression and, 17  
     unresolved questions, 18-19  
     vasodilator neuroendocrine mechanisms, 13-15
- Nicardipine, radionuclide cineangiographic assessment of effects of, 349
- Ninety-degree rule, 587
- Nitinol alloy, 675, 708
- Nitrates, 73-85, 87. See also *Isosorbide dinitrate (ISDN)*.  
     ejection fraction effects of, 76-77  
     exercise tolerance effects of, 74  
     hemodynamic effects of, 73-74  
     limitations of, nitrate resistance, 77-79  
     nitrate tolerance, 79-82  
     side effects, 77  
     mechanism of action, 73  
     research suggestions, 82-83  
     survival effects of, 74-76
- Nitric oxide, 400, 417-418
- Nitro blue tetrazolium, 177
- Nitroglycerin, intracoronary, with Gianturco-Roubin coronary stent procedure, 639  
     radionuclide cineangiographic assessment of, 349
- Nitroprusside, 95
- Nonhirudin peptide, 407
- Norepinephrine, cellular effects of, 15-17  
     plasma levels in congestive heart failure, 10-11, 15  
     mortality and, 32
- Normalcy rate, 205
- Novacor left ventricular assist device, 147-148
- NSVT. See *Ventricular tachycardia, nonsustained (NSVT)*.
- Nuclear magnetic imaging, of aorta-iliac-femoral artery systems, in percutaneous cardiopulmonary bypass support, 551-552
- Obesity, imaging methods in patients with, 388  
     as risk factor, 5
- Ouabain, 177
- Pacemaker, temporary, during high-speed rotational ablation, 607
- Pacing, atrial, 274
- Papaverine, pharmacologic vasodilation with, mechanisms of, 225
- PARIS I (Persantine and Aspirin in Coronary Heart Disease study, I), 455-456
- PARIS II (Persantine and Aspirin in Coronary Heart Disease study, II), 457
- Patency, infarct artery, myocardial perfusion scintigraphy of, 251-252
- Paving, polymeric endoluminal, 715-737  
     background, 715-720  
     rationale, 716-720  
     intraluminal therapy development as, 719-720  
     pathophysiology of abrupt closure as, 718-719  
     stent limitations as, 716-718  
     clinical applications of, potential, 733-734  
     defined, 719-720  
     process of, 720-726  
     description, 720  
     forms of, 720-726  
     gel, 722-725  
         clinical applications of, 734  
         experimental studies, 731-733  
     liquid, 725-726  
     solid, 720-722  
         clinical applications of, 734  
         experimental studies, 726-731
- Perfusion. See also *Retroperfusion*.  
     coronary, antegrade systems for, 554  
     with perfluorocarbon, 555  
     Perfusion agents, radiolabeled. See also specific agents.  
     physiologic properties of, 169-185  
     background of, 169-170  
     myocardial kinetics of, background of, 177  
     cell culture studies of, 170-171  
     isolated heart model of, 171-173  
     in vivo models of, 173-177  
     myocardial viability assessment of, cell culture studies of, 177-178  
     isolated heart model studies of, 178  
     in vivo studies of, 178-181  
     with technetium, 187-198, 385  
     advantages of, 187, 192-193  
     in coronary artery disease diagnosis, 191-192  
     in dual-isotope imaging, 196  
     in gated imaging, 193  
     imaging protocols, 189-191  
     myocardial infarction assessment with, 194  
     myocardial viability studies with, 194-195  
     newer agents, 195-196  
     pharmacokinetics of, 187-189  
     risk assessment with, 193-194
- Persantine. See *Dipyridamole*.
- Persantine and Aspirin in Coronary Heart Disease study, I, 455-456  
     II, 457
- Pertechnetate, technetium-99m, 195
- PET imaging, 303-304  
     background, 303  
     blood flow evaluation with, 303-315, 309-312  
     coronary artery disease detection with, 306-307  
     in high-speed rotational ablation analysis, 599  
     metabolic studies with, 303-315  
     myocardial kinetic studies with, in vivo, 179  
     myocardial perfusion scintigraphy with, 199, 266-268  
     myocardial viability assessment with, 266-268, 307-309, 327-328  
     techniques for, 309  
     normal human myocardium studies with, information display and findings in, 304-306  
     percutaneous transluminal coronary angioplasty patient evaluation with, 374
- Phenindione, 463, 465
- Phenprocoumon, 455
- Phenylephrine, 546
- Phosphodiesterase inhibiting agents, 64, 67-70, 87  
     pharmacology of, 423-424
- Picotamide, 428
- Pierce-Donachy ventricular assist device, 146-147
- Pimobendan, 67, 69
- Pirbuterol, 64, 66

- Piroximone, 64, 65, 67-68
- Planar imaging, 385
- coronary artery disease detection with, 386
    - technetium-99m sestamibi for, 191-192
    - thallium-201 imaging vs, 213-214
  - technetium-99m teboroxime for, 192
  - gated, technetium-99m sestamibi with, 216
  - for ischemia, resting myocardial, 387
  - left main/triple-vessel disease detection with, 209-210
  - myocardial infarction analysis with, technetium-labeled perfusion agents for, 194
  - myocardial perfusion scintigraphy with, 200-201
  - technetium-99m teboroxime for, 190
  - thallium-201 and, 199
    - individual coronary artery disease detection with, 208-209
    - qualitative analysis with, 203
    - quantitative analysis with, 203-205
- Plasmin, 405
- Plasminogen, 405
- Plasminogen activator, tissue-type, 405, 564, 573
- abrupt closure of coronary artery and, 575
  - in ECSC Trial, 561
  - in PAMI Trial, 564-565
  - recombinant, 510
  - in TAMI Phase I Trial, 560
  - in TIMI Phase IIA Trial, 560
  - total coronary artery occlusion and, 578
- Platelet plug, 400
- Platelets, adhesion of, inhibitors of, pharmacology of, 424
- deposition and recruitment, 399-400
  - glycoprotein IIb/IIIa receptor antagonists, pharmacology of, 424-427
  - inhibition of, pharmacologic, 400, 412-421, 423-427.
    - See also specific agents.
  - monolayer of, 400
  - release reaction of, 400
  - role of, 411
    - in restenosis, 527-528
  - vessel wall interaction modulators, pharmacology of, 427-428
- Polyanhydride, 702
- Polyester, 702
- Polyethylene terephthalate (PET), 701
- Poly-L-lactic acid, 702, 703, 719
- Polymer, biodegradable. *See also Paving, polymeric endoluminal.*
- as drug delivery system, 701
  - defined, 701
- Polymer coating, of Wallstent, 692-693
- Polymeric endoluminal paving. *See Paving, polymeric endoluminal.*
- Polyorthoester, 702
- Polyurethane urea, 701
- Positron emission tomography (PET). *See PET imaging.*
- Potassium loss, with increased aldosterone production, 109-110
- Potassium-sparing diuretics, 43
- Pregnancy, aspirin during, deep venous thrombosis prophylaxis with, 510
- deep venous thrombosis therapy during, 513
- Prevalence, 1-7
- Prevention of Arterial Thromboembolism in Patients with Nonvalvular Atrial Fibrillation in General Practice, 502
- Primary Angioplasty in Myocardial Infarction (PAMI) Trial, 564-565, 565
- Proarrhythmias, 126
- Prognosis, 1-7
- Prospective Randomized Milrinone Survival Evaluation (Promise), 93-94
- Prospective Randomized Study of Ventricular Failure omise)
  - and the Efficacy of Digoxin (PROVED), 56-57, 59
- Prostacyclin, pharmacology of, 420-421
- Prostaglandins, pharmacology of, 420-421
- Protamine, 554
- Protein C, 404, 406, 407, 421, 433
- Protein S, 404, 406, 421, 433
- Prothrombinase complex, 402
- Protocol, imaging, 386
- myocardial perfusion scintigraphic, technetium-99m sestamibi in, 212-213
  - reinjection, thallium-201 for, 321-322
  - rest, thallium-201 imaging in, 324-326
  - rest-redistribution, thallium-201 imaging in, 323-324
  - rest-stress, 189, 213
    - dual-isotope SPECT imaging for. *See Dual-isotope SPECT.*
    - same day, SPECT imaging for, 213
    - separate day, SPECT imaging for, 213
    - stress-rest, 189, 213
    - technetium-99m sestamibi and, 189-190
    - technetium-99m teboroxime and, 190-191
- Proto-oncogene, 531
- PTCA. *See Angioplasty, coronary, percutaneous transluminal.*
- Pulmonary disease, chronic, first-pass radionuclide angiographic imaging of, 369
- Pyrophosphate, technetium-99m, infarct-avid imaging with, clinical applications of, 294-296
- scintigraphic principles of, 290-291
  - technical aspects of, 293
- Q-3, technetium-99m, 195-196
- Q-12 (furifosmin), 195
- Quinapril, 107
- Quinapril Ischemic Event Trial (QUIET), 111-112
- Ramipril, 161
- Randomized aldosterone evaluation pilot study (RALES), 110
- Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme (RADIANCE), 56-57
- Recanalization, for subacute coronary stent thrombus formation, 659
- Recommendations, of American College of Chest Physicians, for antithrombotic therapy with heart valve replacement, 492
- Consensus Conference on Antithrombotic Therapy (1992), 462, 474, 477, 480, 487
- Redistribution, 200, 209, 276
- late 24-hour, thallium-201 in, myocardial viability studies with, 321
  - radionuclide perfusion agent, 176, 249
  - thallium-201, myocardial viability studies with, 319-320
- Regurgitation, valvular, direct-acting vasodilators and, 94-98
- Remodeling, ventricular, 155-163
- angiotensin II a.d, 12
  - defined, 15
  - postinfarction, 156-157

- angiotensin-converting enzyme inhibitors and, clinical trials, 160-162  
 experimental studies, 158-160  
 morphologic and biochemical changes in, 157-158
- Renin-angiotensin system, 9, 11-12  
 activation of, effects, 88  
 mechanism of action, 107-108  
 mortality and, 32
- blockade of, 101-114  
 aldosterone antagonists and, 109-110  
 by angiotensin-converting enzyme inhibitors, 101-105  
 research results, implications, 105-107  
 angiotensin II receptor antagonists and, 110  
 future studies of, 108-109  
 mechanism of action, 107-108  
 renin inhibitors and, 110  
 secondary prevention of ischemic heart disease and, angiotensin-converting enzyme inhibitor for, 110-112
- RESCUE Trial, 561
- Restenosis, after excimer laser treatment, 591  
 after Gianturco-Roubin coronary stent procedure, 645-646  
 management of, with stent, 659-660  
 mechanism of, with stent, 659  
 multicenter trial, with Wiktor coronary stent, 668-669  
 pathogenesis of, 685  
 after percutaneous transluminal coronary angioplasty, 527-531, 611, 651, 699  
 background, 595  
 clinical trials, 528-530  
 mechanism, 527  
 platelet and thrombin role in, 527-528  
 therapy for, future directions, 530-531
- percutaneous transluminal coronary angioplasty patients for, radionuclide imaging evaluation of, greater than 6-month, 381  
 immediate, 373, 375-377  
 less than 6-month, 377-381  
 radionuclide ventriculography evaluation of, 381
- prevention, with stent, 579  
 process of, 699-700  
 after Rotablator catheter use, 602-603  
 after stent placement, 716-717  
 after Strecker stent, 679  
 therapeutic thrombolysis and, 581-582  
 after transluminal extraction coronary atherectomy, 616  
 treatment, with stent, metallic, 700-701  
 Palmaz-Schatz, 700
- Retroperfusion. See also *Perfusion*.  
 coronary sinus, synchronized, in percutaneous cardiopulmonary bypass support, 555
- Ridogrel, 428
- Risk factors, 4-6
- Risk stratification, post myocardial infarction, 276-280  
 preoperative, for noncardiac surgery, 282-283  
 for peripheral vascular disease surgery, 280-282  
 technetium-labeled perfusion agents for, 193-194
- RNCA. See *Cineangiography, radionuclide (RNCA)*.
- Rotablator catheter. See *Catheter, rotablator*.
- ROTACS. See *Catheter, low-speed rotational angioplasty*.
- Rotenone, 177
- Rubidium-82, 169  
 for myocardial kinetic studies, in vivo, 174-175  
 for myocardial viability studies, in vivo, 178-181  
 uptake and retention, in PET imaging, 309
- Rule of two-thirds, 587
- Salbutamol, 64, 66
- Salvage index, 250
- SAMI (Streptokinases and Angioplasty in Myocardial Infarction) Trial, 563
- Scatter, correction of, technetium-99m sestamibi for, 216
- Scintigraphy, myocardial perfusion, 199-222  
 background, 199  
 coronary artery disease evaluation with, 271-272  
 prognostic value of, normal exercise test results, 273  
 normal nonexercise test results and, 274  
 other radionuclide markers, 274-276  
 positive exercise test results, 272-273  
 positive nonexercise test results, 274  
 coronary artery disease prognosis and, 271-287  
 function imaging and, with first-pass radionuclide angiography, 367-368  
 in myocardial infarction detection. See *Myocardial infarction*.  
 and percutaneous transluminal coronary angioplasty, patient evaluation, immediately after, 375-377  
 later after, 381  
 for restenosis, 377-381  
 patient selection, 373-383, 374-375  
 background, 373-374  
 during pharmacologic stress testing. See *Stress testing, pharmacologic*.  
 with technetium-99m sestamibi, quantitative analysis of images, 213  
 technical characteristics, 212-213  
 unique applications, 215-216  
 with thallium-201, acquisition protocols, with planar imaging, 200-201  
 with SPECT imaging, 201-202  
 coronary artery disease detection with, 203-208  
 in individual arteries, 208-209  
 severe and extensive, 209-212  
 myocardial kinetics, 199-200  
 quantitative analysis, 202  
 stress testing methods, 202-203  
 vs planar technetium-99m sestamibi, for coronary artery disease, 213-214  
 vs SPECT technetium-99m sestamibi, for coronary artery disease, 214-215
- Second International Study of Infarct Survival (ISIS-2) trial, 446, 448
- Sestamibi, technetium-99m, 385  
 attenuation and scatter correction with, 216  
 coronary artery disease diagnosis with, 191-192  
 coronary artery disease evaluation with, planar images vs thallium-201 images in, 213-214  
 SPECT images vs thallium-201 images in, 214-215  
 dual-isotope imaging with, 216  
 myocardial perfusion SPECT imaging and, 261-270  
 background of, 261  
 clinical implications of, 269-270  
 in coronary artery disease, 264-265  
 cost considerations of, 268-269  
 defect reversibility assessment of, 265-266  
 image quality of, 266-268  
 protocols for, separate acquisition, 262-263, 268  
 simultaneous acquisition, 262  
 quantitative analysis of, 266  
 gated studies with, 216  
 imaging protocols with, 189-190  
 myocardial infarction diagnosis with, 194  
 in on-going infarction, limitations of, 256  
 myocardial kinetic studies with, in cell culture, 170-171  
 in isolated heart models, 171-173  
 in vivo models, 173-177



## Sestamibi (Continued)

- myocardial perfusion scintigraphic studies with, background of, 212
- image acquisition parameters, 213
- images from, quantitative analysis of, 213
- of myocardial infarction, collateral flow studies, 252-253
  - infarct artery patency and, 252
  - infarct size models and, 250, 253-255
  - in myocardial salvage studies, 250
  - in myocardium at risk studies, 249
  - no ST-segment elevation, 255-256
- patient study protocols, imaging, 212-213
  - stress mode, 212
- processing parameters, 213
  - of unstable angina, 257-258
- myocardial viability studies with, 194-195, 326-327
  - in cell culture, 177-178
  - in isolated heart model, 178
  - in vivo, 178-181
- in perfusion-function imaging, with first-pass radionuclide angiography, 367
- pharmacokinetics of, 187-189
- in planar imaging of ischemia, resting myocardial, 387
- redistribution of, 249
- ventricular function assessment, first-pass and myocardial perfusion, 215-216
- Shock, cardiogenic, cardiopulmonary bypass support and, 544, 546, 547, 550
  - termination of, 548
  - as predictor of in-hospital mortality, 566
- Silicone, 701
- Simplastin, 488
- Single-photon emission computed tomography (SPECT) imaging. *See SPECT imaging.*
- Sinus rhythm, maintenance, 497
- Society for Clinical Trials study, 456-457
- Sodium retention, dietary sodium regulation and, 39
  - edema pathophysiology and, 37-39
- SPAF-II study, 501
- SPAF study, 498-500
- SPECT imaging, 189-190, 336, 385
  - coronary artery disease detection with, 386
  - functional assessment studies with, 387
  - left main/triple-vessel disease detection with, 210
  - of myocardial infarction, with technetium-labeled perfusion agents, 194
    - with technetium-99m sestamibi vs thallium-201 imaging, 214-215
  - in myocardial perfusion scintigraphy, 201-202, 340
  - percutaneous transluminal coronary angioplasty patient evaluation with, 374-375
  - radionuclide cineangiographic applications of, 338
  - limitations of, 350-351
    - with technetium-99m sestamibi, attenuation and scatter correction, 216
    - coronary artery disease diagnosis with, 191-192
    - gated imaging with, 216
  - with technetium-99m tetrofosmin, 195
  - with thallium-201, 199
    - individual coronary artery disease evaluation with, 209
    - qualitative and quantitative analysis, 205-207
- SPINAF (Stroke Prevention in Atrial Fibrillation) trial, 499-500
- Spirinolactone, 109-110
- Stainless steel alloy, in Wallstent, 689, 692
- Starr-Edwards prosthesis, 490

- Stenosis, aorto-ostial, excimer laser treatment of, clinical results, 589
  - of saphenous vein graft, excimer laser treatment of, clinical results, 588-589
- Stent, alternative to, 715
  - biliary, Palmaz-Schatz, 620
    - in coronary circulation, 657-658
  - bioabsorbable, Cleveland Clinic/Mayo/Thoraxcenter, 703-705
    - Duke, 705
    - heparin-coated, 708
    - Kyoto University, 703
  - biodegradable, 699-713
    - background, 699-700
    - versus metallic, background, 700-701
  - closure with Gianturco-Roubin coronary stent procedure, 644-645
- coronary. *See also Wallstent.*
  - for acute myocardial infarction, 567
  - adjunctive thrombolysis and, 578-579
  - flex-. *See Stent, coronary, Gianturco-Roubin.*
  - Gianturco-Roubin, 578, 631-649, 690, 691, 694-695, 717
    - for abrupt closure, 700
    - additional equipment with, 635-636
    - background, 634-635
    - clinical results with, 642-644
    - complications, 644-646
    - contraindications, 637
    - design of, 635
    - drug therapy, adjunctive, 638-642
    - economic considerations, 646-647
    - future applications of, 647
    - patient care, intraprocedure, 639
      - postprocedure, 639-642
      - preprocedure, 638-639
    - patient selection, 637
    - technique, 637-638
  - Palmaz-Schatz, 651-663, 690, 692, 716-717
    - cost considerations, 660
    - delivery system for, 652
    - development of, 651-652
    - for failed coronary artery percutaneous transluminal angioplasty, 656-657
    - future developments, 660-661
    - heparin-coated, 660-661, 708
    - indications for, 652-653
    - in native coronary arteries, elective use, 653-655
    - patient selection for, 652-653
    - restenosis with, 659-660
    - for saphenous vein graft disease, 657
    - versus Strecker stent, 683
    - thrombolysis with, 658-659
  - placement, in percutaneous cardiopulmonary bypass support, 553-554
- Wiktor, 665-671, 692
  - advantages of, 670-671
  - background, 665-666
  - clinical experience with, 667-670
    - bailout trial, 669-670
    - multicenter restenosis trial, 668-669
  - complications with, 670
  - disadvantages of, 671
  - procedure, 666-667
- custom, 661
- heparin-coated, 660-661, 686
- ideal, 701
- intracoronary. *See Stent, coronary.*
  - limitations of, polymeric endoluminal paving to overcome, 716-718

- nitinol, drug delivery studies with, 708  
 noncoronary, use in coronary circulation, 657-658  
 polymeric, 701-705  
   bioabsorbable, 702-705  
     background, 702  
     biocompatibility of, 703  
     biodegradation of, 702-703  
     local therapy with, 705-709  
       background, 705-706  
       devices available for, 706-708  
       drugs for, 708  
       gene, 708-709  
       types of, 702, 703-705  
   as drug delivery system, 701  
   nonbioabsorbable, 701-702  
 restenosis with, management of, 659-660  
   mechanism of, 659  
**Strecker, 673-687**  
   background, 673  
   for carotid arteries treatment, 684-685  
   coated and drug-releasing, 685-686  
   for coronary artery bailout procedure, conclusions, 684  
   patients and methods, 683  
   results, 683-684  
   description, 673-675  
   for distal abdominal aorta treatment, discussion, 678-680  
   patients and methods, 676-677  
   results, 677  
   for femoropopliteal artery treatment, discussion, 679-680  
   patients and methods, 676-677  
   results, 677-679  
   for renal artery treatment, discussion, 682-683  
   patients and methods, 681  
   results, 681-682  
**Stent jail, 671**  
**Stent Restenosis Study (STRESS), 653-655, 700, 717**  
**Stockings, graduated compression, 508**  
   for venous insufficiency treatment, 514  
**Streptokinase, 459-460, 510, 563, 564, 573-574**  
   abrupt closure of coronary artery and, 575-576  
**Streptokinases and Angioplasty in Myocardial Infarction (SAMI) Trial, 563**  
**Stressors, pharmacologic. See specific stressors; Stress testing, pharmacologic, stressors for.**  
**STRESS (Stent Restenosis Study), 653-655, 700, 717**  
**Stress testing, exercise, 385**  
   with first-pass radionuclide angiography, prognostic importance of, 366-367  
   with myocardial perfusion scintigraphy, 202, 276-277  
     normal results of, prognostic value of, 273  
   with radionuclide cineangiography, 339, 351  
     prognostic value of, 340-348  
**SPECT and radionuclide cineangiography during, 350-351**  
   technetium-99m sestamibi myocardial perfusion imaging with, 212  
   protocols for, 212-213  
**treadmill, 202**  
   with radionuclide angiography, 192-193  
   vs pharmacologic stress testing, with thallium-201 scintigraphy, 207  
   nonexercise, with myocardial perfusion scintigraphy, prognostic value of, 274  
   pharmacologic, 385  
     with adenosine, in myocardial perfusion scintigraphy, 202-203  
     for coronary artery disease detection, stressors for, 228-232  
     for coronary artery disease risk stratification, 235  
       before cardiovascular surgery, 235-238, 238-240  
       with dipyridamole, in myocardial perfusion scintigraphy, 202-203  
     following myocardial infarction, 277-279  
     left ventricular cavity dilation with, 232-233  
     lung uptake with, increased, 232-233  
     with myocardial perfusion scintigraphy, 202-203, 223-245  
       background, 223  
       coronary blood flow and, 223-224  
       early post myocardial infarction risk stratification, 279  
       following myocardial infarction, 277-279  
       with radionuclide cineangiography, 339-340  
       and SPECT, 350-351  
     stressors for. *See also Adenosine; Dipyridamole; Dobutamine; Papaverine.*  
       contraindications, 234-235  
       hemodynamic effects of, 226-228  
       potency of, 225-226  
       side effects of, 233-234  
       ST-segment depression with, importance of, 234  
       with technetium-99m sestamibi myocardial perfusion imaging, 212  
       protocols for, 212-213  
       vasodilation mechanisms and, 224-225  
       with technetium-99m sestamibi and dual-isotope rest thallium-201 imaging, 216  
       with thallium-201 scintigraphy, of myocardial viability, 320-321  
     time-efficiency considerations, 388  
**Stroke, with anticoagulant therapy, incidence of, 472-473**  
   with atrial fibrillation, prevention, 497-502  
   risk of, 496-497  
   short-term risk, 500  
   embolic. *See Embolism.*  
**Stroke Prevention in Atrial Fibrillation trial, 499-500**  
**ST-segment depression, 234**  
**ST-segment elevation, lack of, in myocardial infarction, myocardial perfusion scintigraphy of, 255-257**  
**Studies of Left Ventricular Dysfunction (SOLVD), 18, 161**  
   angiotensin-converting enzyme inhibitor data, 12  
   circulatory neurohormonal level data, 13-14  
   diastolic/systolic dysfunction data, 10  
   digoxin in patients in, 51  
   diuretic effects data, 9-10  
   mortality, 26  
   angiotensin-converting enzyme inhibitor effect on, 102-105, 108-109  
     implications of, 105-107  
     from ventricular arrhythmias, 124  
   renin-angiotensin system activation data, 88  
   sudden cardiac death rates in, 116-117  
   survival predictors in, 28  
**Sudden cardiac death, 6, 124**  
   angiotensin-converting enzyme inhibitor effects on, 105  
   ventricular arrhythmias and, 31, 116-117  
   treatment, 124  
**Sulfinpyrazone, 400, 445**  
   for myocardial infarction, secondary prevention, *Anturane Reinfarction Italian Study, 458*  
   *Anturane Reinfarction Trial Research Group, 457-458*  
**Surgery, cardiovascular, coronary artery disease risk stratification, with pharmacologic stress testing, 235-238**

## Surgery (Continued)

- deep venous thrombosis prophylaxis with, 509-510
- noncardiac, preoperative risk stratification, with myocardial perfusion scintigraphy, 282-283
- peripheral vascular disease, preoperative risk stratification, with myocardial perfusion scintigraphy, 280-283
- Survival And Ventricular Enlargement (SAVE) study, angiotensin-converting enzyme inhibitor data, 91
- mortality rates, 105
- from ventricular arrhythmias, 124-125
- results, 161
- ventricular arrhythmias in, prevalence of, 119
- Sympathetic nervous system, 9, 10-11
- Syndrome X, 311
- Systolic dysfunction, mortality and, 10, 26-27

## TAMI (Thrombolysis and Angioplasty in Myocardial Infarction) Trial, phase I, 560

Tantalim-178, 361

Tantalum, 665, 673, 675, 703

Taprosten, 420

TAUSA (Thrombolysis and Unstable Angina) study, 526

Teboroxime, technetium-99m, 252, 385

imaging protocols with, 190-191

in myocardial kinetic studies, in cell culture, 170-171

in vivo, 175-177

in myocardial viability studies, in cell culture, 177-178

in isolated heart model, 178

in vivo, 181

pharmacokinetics of, 188-189

Technetium dioxime, 169

Technetium-labeled perfusion agents. *See* Perfusion agents, radiolabeled, with technetium.

Technetium-99m, half-life of, 212

redistribution of, 249

Technetium-99m sestamibi. *See* Sestamibi, technetium-99m.

Tetrafosmin, technetium-99m, 195

TFPI (tissue factor pathway inhibitor), 401-402, 403, 434

Thallium-201, 169-170, 385, 552

disadvantages of, 187

dual-isotope imaging with, 196

myocardial perfusion SPECT and, background of, 261

clinical implications of, 269-270

coronary artery disease detection with, 263-265

cost considerations of, 268-269

defect reversibility assessment, 265-266

image quality, 266-268

protocols, 261-263

separate acquisition, 262-263

advantages of, 268

simultaneous acquisition, 262

quantitative analysis, 266

myocardial defects identified with, 200

myocardial kinetic studies of, 199-200

in cell culture, 170-171

in isolated heart models, 172-173

in in vivo models, 174-177

in myocardial perfusion scintigraphic studies. *See*

Scintigraphy, myocardial perfusion, with thallium-201.

of myocardial infarction, 249

of unstable angina, 237-258

myocardial viability studies with, 387

in cell culture, 177-178

in isolated heart models, 178

late 24-hour redistribution imaging for, 321

rationale, 318-320

reinjection protocol, 321-323

rest-redistribution imaging, in severe left ventricular dysfunction, 323-324

rest testing, in unstable coronary syndromes, 324-326

stress testing and, 320-321

in in vivo studies, 178-181

with planar imaging, 283

prognostic value in coronary artery disease patients, 272-273

pulmonary uptake of, 211

redistribution of, 249

in myocardial viability studies, 319-320

sensitivity and specificity of, referral bias and, 205

with SPECT imaging, coronary artery disease detection, vs technetium-99m sestamibi, 261

qualitative and quantitative analysis, 205-207

washout rate of, planar image detection of, 210-211

Thermoforming, intraluminal, in solid polymeric endoluminal paving, 720

Thiazides, 40-43

Thoratec ventricular assist device, 150

Thrombin, 400

activity of, 421

in arterial thrombosis, 518-519

generation of, accelerated, 402-403

coagulation initiation and, 401-402

inhibitors of, 403-405

hirudin and hirudin derivatives, 406-407

nonhirudin peptide, 407

pharmacology of, 432-434

synthetic, pharmacology of, 431

receptors of, antagonists, pharmacology of, 431-432

restenosis role of, 527-528

Thromboembolism. *See* Embolism.

Thrombolysis, therapeutic, for abrupt closure of

coronary artery, 575-577, 578-579

after percutaneous transluminal coronary

angioplasty, 525-526

for acute myocardial infarction, background, 573

coronary interventional techniques and, 573-584

percutaneous transluminal coronary angioplasty

after. *See* under Myocardial infarction, acute.

characteristics of, 573-574

complications with, 580-581

for deep venous thrombosis, 510-512

perfusion catheter selection and placement for, 580

post myocardial infarction, risk stratification with myocardial perfusion scintigraphy for, 279-280

for systemic embolism prevention, 482

restenosis and, 581-582

for total coronary artery occlusion, 577-578, 578-579

Thrombolysis and Angioplasty in Myocardial Infarction (TAMI), Phase I Trial, 560

Thrombolysis and Unstable Angina study, 526

Thrombolysis in Myocardial Infarction (TIMI), Phase IIA Trial, 560

Phase IIB Trial, 562

Phase IIIA Trial, 574

Thrombomodulin, 407

Thrombomodulin/protein C/protein S system, 403-405

Thromboplastin, human brain, 488, 489, 503

rabbit brain, 488, 489, 503

Thrombosis, 411-412

antithrombotic agents for, 405-407

arterial, mechanisms, 399-476

thrombin role in, 428

coagulation factor activation, 400-405

- coronary, subacute, with Palmaz-Schatz coronary stent, 658-659  
management of, 659  
deep venous, 505-516  
incidence after anticoagulant therapy, 473  
prevention, background, 505-508  
nonpharmacologic, 508  
pharmacologic, 508-510  
treatment, 510-514  
with anticoagulant agents alone, 512  
with chronic venous insufficiency, 514  
emotional support, 514  
with inferior vena caval interruption, 513-514  
with isolated calf vein thrombosis, 513  
with low molecular weight heparin, 512-513  
with oral anticoagulation, with cancer, 513  
duration and intensity of, 513  
in pregnancy, 513  
with thrombolytic agents, 510-512  
defined, 399  
fibrinogen, fibrin, and fibrinolysis in, 405  
intracoronary, clinical considerations, 574-575  
intrastent, 716  
isolated calf vein, treatment of, 513  
left ventricular, 477  
echocardiography for, 478  
in myocardial infarction, 479  
noninvasive diagnostic tests for, 478  
platelet deposition and recruitment, 399-400  
with Strecker stent, 679  
venous, idiopathic versus postoperative, treatment differences, 512  
thrombin role in, 428  
Thromboxane A2 blockers, 529  
Tick anticoagulant protein, recombinant, 407, 434  
after percutaneous transluminal coronary angioplasty, 524, 528  
Ticlopidine, 400  
for Gianturco-Roubin coronary stent procedure, 642  
pharmacology of, 419-420  
for restenosis prevention after percutaneous transluminal coronary angioplasty, 529  
for Strecker stent procedure in carotid artery, 684  
TIMI. See *Thrombolysis in Myocardial Infarction (TIMI)*.  
Tissue factor, for abrupt closure after percutaneous transluminal coronary angioplasty, 525  
Tissue factor pathway inhibitor, 401-402, 403, 434  
Tracers. See *Perfusion agents, radiolabeled*.  
Transplantation, circulatory assist devices as bridge to, 150, 151-152  
Treadmill. See *Stress testing, exercise, treadmill*.  
Triphenyl tetrazolium chloride, 177  
Triton X-100, 187  
cell injury induced by, 178  
Ultrasonography, 289  
intravascular, 717  
in high-speed rotational ablation analysis, 597-598  
postoperative elimination of warfarin and, 661  
with transluminal extraction-endarterectomy catheter, 616-617  
United Kingdom transient ischemic attack trial, 447-448  
United States Physicians' Health Study, aspirin therapy trials, 446-447  
Urokinase, 573-574, 580, 581  
abrupt closure of coronary artery and, 575  
deep venous thrombosis treatment with, 511-512  
total saphenous vein occlusion and, 578  
Vascular anticoagulant, 434  
Vascular disease, peripheral, preoperative risk stratification, with myocardial perfusion scintigraphy, 280-282  
Vasodilation, coronary, contraindications, 202  
neuroendocrine mechanisms and, 13-15  
pharmacologic, 385  
mechanisms of, 224-225  
Vasodilator therapy, 87-99  
background, 87-88  
direct-acting, 87, 91-94  
calcium channel blockers, 93  
hydralazine, 92-93  
milrinone, 93-94  
valvular regurgitation effects of, 94-98  
future directions, 98  
indirect-acting, 87, 88-91  
angiotensin-converting enzyme inhibitors for, 88-91  
vasoconstriction and, 88  
ventricular arrhythmias and, 123-124  
Vein, saphenous, bypass grafts, transluminal extraction catheter indications for, 617-619  
graft disease, less-shortening Wallstent treatment of, 695-696  
noncoronary stent use in, 657-658  
Palmaz-Schatz stent use in, 657  
stenoses with, excimer laser treatment, 588-589  
thrombus formation and, 575, 577-578  
Wallstent use in, 693  
Vena cava, inferior, interruption, treatment of, 513-514  
Venom, snake, 426  
Venous insufficiency of legs, 505  
Ventricle, left, transient ischemic dilation of, 211-212  
Ventricular arrhythmias, amiodarone and, 127-128  
angiotensin-converting enzyme inhibitor effects on, 123-125  
antiarrhythmic drugs for, 125-126  
background, 115  
beta-blocker therapy and, 126-127  
electrolyte imbalance and, 123  
electrophysiologic testing and, 119  
mode of death and, 115-116  
mortality predictor, 30-32  
pathophysiology of, 120-121  
precipitating factors, correction of, 122-123  
prevalence of, 117-119  
prognostic importance of, 117-119  
recurrent myocardial ischemia and, 122-123  
signal-averaged electrocardiography and, 119-120  
sudden cardiac death and, 31, 116-117  
treatment considerations, 115-132  
treatment questions, 122  
trials of, ongoing, 129  
vasodilator therapy effects on, 123-125  
Ventricular cavity, left, dilation, with thallium-201 imaging, prognostic value, 275-276  
dilation of, with adenosine, 232-233  
with dipyridamole, 232-233  
Ventricular diastolic performance, left, radionuclide cineangiography and, 339  
Ventricular ejection fraction, left, 335, 337  
first-pass radionuclide angiographic measurements of, 362  
prognostic importance of, 366  
right, first-pass radionuclide angiographic measurements of, 359-360, 362  
Ventricular failure, postcardiotomy, circulatory assist devices for, 149-150  
Ventricular function, abnormal, systemic embolism prevention in patients with, 477-485

Ventricular function (*Continued*)

- antithrombotic therapy for, 479-483
    - background, 477
    - primary and secondary, 477-479
  - beta-blockers and, 134-135
  - first-pass, and myocardial perfusion with technetium-99m sestamibi, 215-216
  - left, assessment of, dual perfusion/function imaging for, 351
    - imaging methods for, 387-388
      - depressed, myocardial viability studies with technetium-99m sestamibi, 326-327
      - PET imaging studies of, 308-309
    - regional, first-pass radionuclide angiographic measurements of, 362
    - right, assessment of, imaging methods for, 387-388
  - Ventricular tachycardia, nonsustained (NSVT), 115
    - electrophysiologic testing of, 119
    - prevalence of, 117-119
  - Ventriculography, radionuclide, 381
    - myocardial infarction diagnosis with, 290
    - myocardial viability assessment with, 328
  - Verapamil, intravenous, radionuclide cineangiographic assessment of, 349
  - Vesnarinone, 69-70
  - Veterans Administration Cooperative Study, of anticoagulant agents for myocardial infarction, long-term, 464
    - short-term, 466-467
    - and systemic embolism, 472-473
    - and venous thromboembolism, 473
  - Veterans Administration Cooperative Study Survival Trial of Antiarrhythmic Therapy (STAT), 128-129
  - Veterans Administration Heart Failure Study (V-HeFT-II), angiotensin-converting enzyme inhibitor data, 12, 91
    - on mortality, 103-105, 108-109
    - implications of, 105-107
  - isosorbide dinitrate, exercise tolerance data, 74
  - survival data, 74-75
  - mortality rate, 18, 25-26
    - predictors, 28, 30
  - from ventricular arrhythmias, 124
  - neurohormonal activation data, 17
  - prognostic data, 17-18
  - ventricular arrhythmias in, 118-119
- Visnarinone, 134
- Vital capacity, reduced, as risk factor, 5
- von Willebrand factor, 399, 425, 426, 520
- von Willebrand factor antagonists, pharmacology of, 424
- von Willebrand's disease, 399, 527
- Wall motion. *See* Heart, wall of.
- Wallstent, coronary, 689-697, 716-717
  - clinical experience with, early, 693
  - later, 693-695
  - contraindications, 696
  - design, 689-692
  - indications, 696
  - less-shortening, 691-692
    - clinical results with, 695-696
    - indications for, 696
  - polymeric coating of, experimental studies, 692-693
  - thrombogenicity of, experimental studies, 692-693
- Warfarin, 464, 466, 470-471, 477. *See* Anticoagulation therapy.
- for deep venous thrombosis prophylaxis, adjusted-dose, 510
- fixed low-dose, 510
- for deep venous thrombosis therapy, 512
- pharmacology of, 421-422
- for restenosis prevention after percutaneous transluminal coronary angioplasty, 530
- sodium, oral preparations, 502-503
- for subacute coronary stent thrombus formation, 659
- elimination of, 661
- for systemic embolism prevention, with atrial fibrillation, clinical trials, 498-502
- with prosthetic heart valve, 491
- Warfarin Reinfarction Study, 470-471, 480
- Washout, diffuse, slow, of thallium-201, 210-211
- Water perfusable tissue index, 309
- Women's Health Study, 448-449
- Xamoterol, 64, 66, 107



